NASDAQ:IMA ImageneBio (IMA) Stock Price, News & Analysis $4.22 +0.17 (+4.20%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$4.24 +0.02 (+0.36%) As of 10/23/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About ImageneBio Stock (NASDAQ:IMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImageneBio alerts:Sign Up Key Stats Today's Range$3.98▼$4.3050-Day Range$4.00▼$5.6952-Week Range$3.90▼$9.10Volume7,869 shsAverage Volume12,535 shsMarket Capitalization$47.90 millionP/E RatioN/ADividend YieldN/APrice Target$28.00Consensus RatingReduce Company Overview ImageneBio, Inc. is a biotechnology company focused on developing molecular diagnostic technologies for precision oncology. The company aims to generate actionable information about cancer biology from blood-based samples, supporting more informed treatment decisions and disease monitoring. ImageneBio’s platform is designed to analyze tumor-derived molecular signals and may support applications such as cancer detection, treatment selection, and monitoring of treatment response or disease progression. Its work is intended to complement conventional tissue-based testing by providing less-invasive access to tumor information. The company is headquartered in Israel and serves the global biopharmaceutical and clinical research markets. Publicly available information about its product portfolio, commercial reach, and leadership team remains limited.AI Generated. May Contain Errors. Read More ImageneBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreIMA MarketRank™: 2.859625668445 of 5 starsImageneBio scored higher than 57% of companies evaluated by MarketBeat, and ranked 397th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingReduce Consensus RatingImageneBio has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.Upside PotentialImageneBio has a consensus price target of $28.00, representing about 563.5% upside from its current price of $4.22.Amount of Analyst CoverageImageneBio has only been the subject of 2 research reports in the past 90 days.Read more about ImageneBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ImageneBio are expected to decrease in the coming year, from ($3.23) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImageneBio is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImageneBio is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImageneBio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.30% of the float of ImageneBio has been sold short.Short Interest Ratio / Days to CoverImageneBio has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImageneBio has recently decreased by 5.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImageneBio does not currently pay a dividend.Dividend GrowthImageneBio does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentImageneBio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for ImageneBio this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImageneBio insiders have not sold or bought any company stock.Percentage Held by Insiders2.22% of the stock of ImageneBio is held by insiders.Percentage Held by Institutions75.00% of the stock of ImageneBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ImageneBio's insider trading history. Receive IMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImageneBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMA Stock News HeadlinesImageneBio (NASDAQ:IMA) Shares Down 1% - Here's What HappenedOctober 20, 2026 | americanbankingnews.comImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 24 at 1:00 AM | Weiss Ratings (Ad)ImageneBio Corporate Event Calendar | NASDAQ:IMASeptember 13, 2026 | benzinga.comImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkSeptember 8, 2026 | markets.businessinsider.comImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkSeptember 8, 2026 | globenewswire.comImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 17, 2026 | markets.businessinsider.comImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 17, 2026 | globenewswire.comSee More Headlines IMA Stock Analysis - Frequently Asked Questions How have IMA shares performed this year? ImageneBio's stock was trading at $6.90 at the beginning of 2026. Since then, IMA shares have decreased by 38.8% and is now trading at $4.22. How were ImageneBio's earnings last quarter? ImageneBio, Inc. (NASDAQ:IMA) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.27. When did ImageneBio's stock split? ImageneBio shares reverse split on the morning of Monday, July 28th 2025.The 1-12 reverse split was announced on Friday, July 25th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of ImageneBio? Shares of IMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImageneBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImageneBio investors own include NVIDIA (NVDA), Rain Enhancement Technologies Holdco (RAIN), Immunic (IMUX), Alphabet (GOOG), Ferroglobe (GSM), Aehr Test Systems (AEHR) and Allogene Therapeutics (ALLO). Company Calendar Last Earnings8/05/2026Today10/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (36m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 IMA's financial health is in the Red zone, according to TradeSmith. IMA has been in this zone for over 36 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMA Previous SymbolNASDAQ:IMA CIK1835579 Webwww.imagenebio.com Phone(857) 343-8292FaxN/AEmployees18Year Founded2016Price Target and Rating Average Price Target for ImageneBio$28.00 High Price Target$28.00 Low Price Target$28.00 Potential Upside/Downside+563.5%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($4.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.99% Return on Assets-34.84% Debt Debt-to-Equity RatioN/A Current Ratio21.47 Quick Ratio21.47 Sales & Book Value Annual Sales$800 thousand Price / Sales59.87 Cash FlowN/A Price / Cash FlowN/A Book Value$11.91 per share Price / Book0.35Miscellaneous Outstanding Shares11,350,000Free Float11,099,000Market Cap$47.90 million OptionableNot Optionable Beta0.74 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:IMA) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
